Skip to content

At 3.5% CAGR, Global Epilepsy Therapeutics Market Size & Share To Surpass USD 18.1 Billion by 2028 | Industry Trends, Value, Analysis & Forecast Report by Zion Market Research – Yahoo Finance

NEW YORK, June 13, 2022 /PRNewswire/ — As per Zion Market Research study, The global epilepsy therapeutics market was valued at over $13 billion in 2021 and is likely to surpass $18.1 billion by the end of 2028. The market is expected to expand at a considerable CAGR of 3.5% during the forecast period.
Key Industry Insights & Finding of the Epilepsy Therapeutics Market Reports:
As per the analysis shared by our research analyst, the Epilepsy Therapeutics Market is expected to grow annually at a CAGR of around 3.5 % (2022-2028).
Through the primary research, it was established that the Epilepsy Therapeutics Market was valued approximately USD 13 Billion in 2021 and is projected to reach to roughly USD 18.1 Billion by 2028.
This is majorly due to higher investments in R&D, increasing awareness and availability of advanced Epilepsy Therapeutics drugs in North America region.
Asia Pacific is witnessing a significant growth in the global Epilepsy Therapeutics market over the upcoming years. Due government initiatives in the field, Increased awareness and technological advancement in field is fueling the growth of global Epilepsy Therapeutics market.
Zion Market Research published the latest report titled as  “Epilepsy Therapeutics Market By Drugs (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Others), By Location (Rural And Urban), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data And Forecasts 2022 – 2028.into their research database.
Epilepsy Therapeutics Market: Overview
Epilepsy Therapeutics refers to chronic neurological disorder which causes constant and unfounded seizures. An individual suffering from Epilepsy Therapeutics tends to have seizures with no explanation. In Epilepsy Therapeutics, the brain activity becomes abnormal, resulting in recurrent seizures that are short episodes of involuntary movement, which may involve a part of the body or the entire body. The increase in the number of accidents and brain injuries and the high rate of post-traumatic Epilepsy Therapeutics (PTE) and post-traumatic seizure (PTS) occurrence in patients with brain injuries are the major factors driving the Epilepsy Therapeutics treatment market.
Furthermore, innovation of new treatment products with better efficiency is expected to further drive this market. Rising number of mergers and acquisitions, new product launches, and increasing number of collaborations and partnerships are some of the latest trends that have been observed in the global Epilepsy Therapeutics market. Besides development of new drugs and treatment options, approval and launch of new products extend profitable opportunities to the Epilepsy Therapeutics treatment market players in the forecast period.
In Addition, development of highly efficacious products, having less side-effects, and better outcomes are likely to propel the Epilepsy Therapeutics market Neurological disorders have become a matter of concern for medical researchers who are looking at optimizing medical treatments. Furthermore, the adoption of anti-epileptics due to increasing seizures and Epilepsy Therapeutics cases, and a rise in research and development is driving the growth of Epilepsy Therapeutics market. .However, factors such as lack of awareness about the condition some developing regions and reluctance to adopt Epilepsy Therapeutics medications in some regions are restraining the growth of the Epilepsy Therapeutics market over the upcoming years.
Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/epilepsy-therapeutics-market
Our Free Sample Report Includes:
2022 Updated Report Introduction, Overview, and In-depth industry analysis
COVID-19 Pandemic Outbreak Impact Analysis Included
172 + Pages Research Report (Inclusion of Updated Research)
Provide Chapter-wise guidance on Request
2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
Includes Updated List of tables & figures
Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
Zion Market Research methodology
Industry Dynamics:
Epilepsy Therapeutics Market: Growth Drivers
Active Government Support and Investments to Expedite Market Growth.
Governmental initiatives to improve the healthcare sectors and higher investments in R&D is anticipated to expand at a notable growth of Epilepsy Therapeutics market during the forecast period. Rise in the number of approvals by government bodies is providing beneficial for the patients in controlling the seizures. This is projected to fuel the adoption of anticonvulsant and boost the market growth over the upcoming years.
Epilepsy Therapeutics Market: Restraints
Epilepsy Medicine shortage to hamper the market growth.
One of the major factors restraining the growth of Epilepsy Therapeutics market during the forecast period is steep rise in medicine shortage. Patients are stockpiling these medicines as there is a shortage of drugs in pharmacies which has raised an alarm in investigating the medicine supply chain globally. This is ultimately affecting the global Epilepsy Therapeutics market as the market becomes less desirable for Epilepsy Therapeutics medications.
Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/epilepsy-therapeutics-market
Global Epilepsy Therapeutics Market: Segmentation
The global Epilepsy Therapeutics market is segregated based on Product, distribution channel, end-user, and region.
Based on distributional channel, the global Epilepsy Therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is projected to dominate the global market. growing number of hospitals, along with adequate reimbursement policies provided by these settings, are some of the major factors responsible for higher growth of hospital pharmacy over the upcoming years. This is eventually responsible for the adoption of antiepileptic drugs by the hospital pharmacies globally.
Based on product market has been classified into first generation Epilepsy Therapeutic second-generation Epilepsy Therapeutics and third generation Epilepsy Therapeutics. The second-generation epilepsy therapeutics segment is expected to hold a significant share of the global epilepsy therapeutics. This is due to increased penetration in the market and better effectiveness as compared to first generation Epilepsy Therapeutics.
Get More Insight before Buying@ : https://www.zionmarketresearch.com/inquiry/epilepsy-therapeutics-market
List of Key Players of Epilepsy Therapeutics Market:
BIAL – PORTELA & CA SA
GlaxoSmithKline Plc
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.
SanofiSA
Sunovion Pharmaceuticals Inc.
UCB SA
Zogenix Inc.
Key questions answered in this report:
What are the growth rate forecast and market size for Epilepsy Therapeutics Market?
What are the key driving factors propelling the Epilepsy Therapeutics Market forward?
What are the most important companies in the Epilepsy Therapeutics Market Industry?
What segments does the Epilepsy Therapeutics Market cover?
How can I receive a free copy of the Epilepsy Therapeutics Market sample report and company profiles?
Report Scope:
Report Attribute
Details
Market size value in 2021
USD 13 Billion
Revenue forecast in 2028
USD 18.1 Billion
Growth Rate
CAGR of almost 3.5 % 2022-2028
Base Year
2020
Historic Years
2016 – 2021
Forecast Years
2022 – 2028
Segments Covered
By Product Type, By Application, and By End Use
Forecast Units
Value (USD Billion), and Volume (Units)
Quantitative Units
Revenue in USD million/billion and CAGR from 2022 to 2028
Regions Covered
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered
U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Companies Covered
BIAL – PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA and Zogenix Inc.
Report Coverage
Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope
Avail customized purchase options to meet your exact research needs.  
https://www.zionmarketresearch.com/custom/91
Free Brochure: https://www.zionmarketresearch.com/requestbrochure/epilepsy-therapeutics-market
Recent Developments:
In January 2020, Eisai Co. Announced the launch of FYCOMPA in China  for the treatment of partial-onset seizures in patients aged 12 years and older.
Regional Dominance:
Increasing awareness and availability.
North America dominates the global market for Epilepsy Therapeutics during the forecast period. This is majorly due to higher investments in R&D, increasing awareness and availability of advanced Epilepsy Therapeutics drugs in this region. Moreover, improved healthcare facilities are driving the market for Epilepsy Therapeutics in North America during the forecast period.
Asia Pacific is witnessing a significant growth in the global Epilepsy Therapeutics market over the upcoming years. Due government initiatives in the field, Increased awareness and technological advancement in field is fueling the growth of global Epilepsy Therapeutics market.
Global Epilepsy Therapeutics Market is segmented as follows:
Epilepsy Therapeutics Market: By Types Covered Outlook (2022-2028)
Anti-Epileptic Drugs
Brain Surgery
Dietary Supplements
Ketogenic Diet
Surgical Therapies
Epilepsy Therapeutics Market: By End Users Covered Outlook (2022-2028)
Ambulatory Surgical Centers
Hospitals& Clinics
Home Care Settings
Neurology Centers
Epilepsy Therapeutics Market: By Products Covered Outlook (2022-2028)
First Generation Epilepsy Therapeutics
Second Generation Epilepsy Therapeutics
Third Generation Epilepsy Therapeutics
Epilepsy Therapeutics Market: By Distribution Channels Covered Outlook (2022-2028)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy-User
Epilepsy Therapeutics Market: By Region Outlook (2022-2028)
North America
The U.S.
Canada
Europe
France
The UK
Spain
Germany
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
Press Release For Epilepsy Therapeutics Market: https://www.zionmarketresearch.com/news/global-epilepsy-therapeutics-market
Browse Other Related Research Reports from Zion Market Research
Cannabis Cultivation Market – Global Industry Analysis: The global Cannabis Cultivation Market accrued earnings worth approximately 147.3 (USD Billion) in 2020 and is predicted to gain revenue of about 359.6 (USD Billion) by 2028, is set to record a CAGR of nearly 14.5% over the period from 2021 to 2028.
Pharmaceutical Sterility Testing Market – Global Industry Analysis: The global Pharmaceutical Sterility Testing Market accrued earnings worth approximately 1.2(USD Billion) in 2020 and is predicted to gain revenue of about 2.3 (USD Billion) by 2028, is set to record a CAGR of nearly 11.9% over the period from 2021 to 2028.
Respiratory Disorders Treatment Market – Global Industry Analysis: The global Respiratory Disorders Treatment market accrued earnings worth approximately 98.9 (USD Billion) in 2020 and is predicted to gain revenue of about 112.5(USD Billion) by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028.
Browse through Zion Market Research’s coverage of the Global Pharmaceutical Industry
Follow Us on: LinkedIn | Twitter | Facebook
About Us
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com/
Blog – https://zmrblog.com/
View original content:https://www.prnewswire.com/news-releases/at-3-5-cagr-global-epilepsy-therapeutics-market-size–share-to-surpass-usd-18-1-billion-by-2028–industry-trends-value-analysis–forecast-report-by-zion-market-research-301566491.html
SOURCE Zion Market Research
Anyone positioning their portfolio for a recession could be making a big mistake.
While not strictly speaking an evangelist, billionaire Mark Cuban has invested in the industry. "In stocks and crypto, you will see companies that were sustained by cheap, easy money—but didn't have valid business prospects—will disappear," Cuban said. The most popular cryptocurrency is currently trading at around $20,657.77, according to data firm CoinGecko.
The Bitcoin carnage continues, as the cryptocurrency breaks $20,000 to trade at its lowest level since 2020.
Investors might take some comfort in crystal-ball gazing by Bank of America, which uses history to plot the next bull market.
When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention. While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding. Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.
‘Bitcoin has already broken down [and is] now seeing significant downside follow-through,’ says Katie Stockton of Fairlead Strategies. Bitcoin believer Yves Lamoureux of Lamoureux & Co., though, thinks ‘bitcoin is fine.’
Already, very early signs of slowing demand and inflation are cropping up. If the economy averts all-out disaster, then stabilizing or declining rates would spur a market rebound.
AMD and Nvidia have been swallowed up in the bear market, with each stock declining at least 50%. Here's how to trade them now.
Retail stocks have taken a beating, but inflation, supply chain woes, and other cost concerns don't tell the full story.
Remember TINA? She’s the one everyone was talking about for the past few years, when it came to buying stocks. ‘There is no alternative,’ they said – pointing out that the near-zero interest rate policy has pushed bond yields down to nothing, and that the housing crisis of 2008 had left investors wary of the real estate market – and stocks were the highest returning game in town. Not anymore. The Federal Reserve has just cracked the whip on rate hikes, implementing a 0.75% increase to the benchm
THE MONEYIST Dear Quentin, My boyfriend and I have been together seven years, and in that time I bought a house. I used my own savings and spent about $10,000 on renovations. My house is a three-bedroom family home, and the tenants cover most of my mortgage.
A decline in earnings could be the next shoe to drop for investors. But it’s all a prelude to what may be the best buying opportunity in decades.
It's no secret that Warren Buffett is one of the best investors alive, delivering investors returns of 20% compounded annually since becoming chief executive officer of Berkshire Hathaway in 1965. Numerous factors can explain Buffett's success, and an important one is his love of dividend stocks. Dividend stocks are a great source of returns in the market and, according to Fidelity, have accounted for 40% of the S&P 500's total returns since 1930.
Bank stocks are dirt-cheap right now, and Citi in particular looks like a bargain. Watch the Fed’s stress-test results—and Warren Buffett’s purchases—to see what might be in store.
Elon Musk is angry. Before getting to the reason for his anger, it should be noted that for more than a decade, from 2003 to almost 2013, the billionaire and Tesla pushed hard for the adoption of electric vehicles despite mockery from rivals and skepticism from financial markets and consumers. Musk and Tesla had, however, found an ear at the White House in the person of Barack Obama, newly elected in 2008.
The cryptocurrency market’s latest swoon has raised the specter of bankruptcy restructuring. In such a case, crypto investors would be navigating uncharted territory.
President Joe Biden and a slew of other democrats have been lashing out against Big Oil, accusing the companies of price gouging
Stocks' stomach-churning start to 2022 raises big questions for the next six months. Here's what you should know.
The cryptocurrency industry was built on swagger, enthusiasm and optimism. All three are in short supply these days, as losses and layoffs mount.
The major indexes sold off on recession fears, while Bitcoin broke another key level. Tesla rival BYD is near a buy point.

source

Share:

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

More Posts